OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Wei on the Potential Implications of the CompassHER2 RD Trial in HER2+ Breast Cancer

June 15th 2021

Mei Wei, MD, discusses the potential clinical implications of the ongoing, phase 3 CompassHER2 RD trial in HER2-positive breast cancer.

Dr. Choudhury on Emerging Treatment Strategies in mCRPC

June 15th 2021

Atish D. Choudhury, MD, PhD, discusses emerging treatment strategies in metastatic castration-resistant prostate cancer.

Dr. Strickler on Selecting Between TAS-102 and Regorafenib in CRC

June 14th 2021

John H. Strickler, MD, discusses factors to consider when selecting between trifluridine/tipiracil and regorafenib for the treatment of patients with colorectal cancer.

Dr. Atkins on Safety Considerations For Neoadjuvant Approaches in Gastric Cancer

June 14th 2021

Katelyn M. Atkins, MD, PhD, discusses safety considerations for neoadjuvant approaches in patients with gastric cancer.

Dr. Ghia on the Efficacy of Ibrutinib/Venetoclax in CLL

June 12th 2021

Paolo Ghia, MD, PhD, discusses results seen with the combination of ibrutinib and venetoclax as a first-line treatment for patients with chronic lymphocytic leukemia.

Dr. Pothuri on the Role of Maintenance Therapy in BRCA+ Ovarian Cancer

June 11th 2021

Bhavana Pothuri, MD, discusses the role of maintenance therapy in BRCA-positive ovarian cancer.

Dr. Phillips on the Toxicity Profile of Venetoclax/Lenalidomide/Rituximab in MCL

June 11th 2021

Tycel Jovelle Phillips, MD, discusses the toxicity profile of the combination of venetoclax, lenalidomide, and rituximab in mantle cell lymphoma.

Dr. Barr on the Next Steps of the RESONATE-2 Trial in CLL

June 11th 2021

Paul M. Barr, MD, discusses the next steps of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Dr. Hillmen on Results With Acalabrutinib in CLL

June 11th 2021

Peter Hillmen, MD, PhD, discusses results reported with acalabrutinib in patients with chronic lymphocytic leukemia, as demonstrated in a phase 3 trial.

Dr. Wang on the Potential Impact of Menin Inhibitors in AML

June 11th 2021

Eunice Wang, MD, discusses the potential impact of menin inhibitors on the treatment of acute myeloid leukemia.

Dr. Shah on Results Seen With Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL

June 11th 2021

Bijal Shah, MD, MS, discusses the results seen with brexucabtagne autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, as demonstrated in the phase 2 ZUMA-3 trial.

Dr. Al-Sawaf on the Efficacy of Venetoclax/Obinutuzumab in Treatment-Naïve CLL

June 11th 2021

Othman Al-Sawaf, MD, discusses the efficacy of venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia, as demonstrated in the phase 3 CLL14 trial.

Dr. Mesa on Data With Momelotinib in Transfusion Independence Responders in Myelofibrosis

June 11th 2021

Ruben A. Mesa, MD, discusses results seen with momelotinib in patients with transfusion-independent myelofibrosis, as demonstrated in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.

Dr. Mesa on Achieving Transfusion Independence in Momelotinib-Treated Myelofibrosis

June 10th 2021

Ruben A. Mesa, MD, discusses the importance of achieving transfusion independence with momelotinib in myelofibrosis.

Dr. Bewersdorf on the Role of Allogeneic Transplant in Myelofibrosis

June 10th 2021

Jan Philipp Bewersdorf, MD, discusses the role of allogeneic hematopoietic cell transplant in myelofibrosis.

Dr. Byrd on the Rationale for the ELEVATE-RR Trial in CLL

June 10th 2021

John C. Byrd, MD, discusses the rationale for the phase 3 ELEVATE-RR trial in chronic lymphocytic leukemia.

Dr. Smith on the Results of the ECOG-ACRIN E1411 Trial in MCL

June 9th 2021

Mitchell R. Smith, MD, PhD, discusses the results of the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Dr. Ailawadhi on the Rationale to Evaluate Lisaftoclax in CLL

June 9th 2021

Sikander Ailawadhi, MD, discusses the rationale to evaluate lisaftoclax in chronic lymphocytic leukemia.

Dr. Zalcberg on the Efficacy of Intra-Patient Dose Escalation With Ripretinib in Advanced GIST

June 7th 2021

John Raymond Zalcberg, discusses the efficacy of intra-patient dose escalation with ripretinib in patients with advanced gastrointestinal stromal tumors, as demonstrated in an analysis of the phase 3 INVICTUS trial.

Dr. Tannir on Results With Telaglenastat/Cabozantinib in mRCC

June 7th 2021

Nazir Tannir, MD, FACP, discusses the efficacy of the combination of telaglenastat and cabozantinib in patients with metastatic renal cell carcinoma, as demonstrated in the phase 2 CANTATA trial.